Chronic Idiopathic Constipation (CIC) Epidemiology Forecast 2025-2034

Chronic Idiopathic Constipation (CIC) Epidemiology Forecast Report Coverage

Expert Market Research's “Chronic Idiopathic Constipation (CIC) Epidemiology Forecast Report 2025-2034” offers comprehensive information on the prevalence and demographics of chronic idiopathic constipation (CIC). It projects the future incidence and prevalence rates of chronic idiopathic constipation (CIC) across various populations. The study covers age and type as major determinants of the chronic idiopathic constipation (CIC)-affected population. The report highlights patterns in the prevalence of chronic idiopathic constipation (CIC) over time and projects future trends based on multiple variables.

Chronic Idiopathic Constipation (CIC): Disease Overview

Chronic idiopathic constipation refers to a gastrointestinal condition characterized by long-term difficulty in passing stools, abdominal discomfort, and infrequent bowel movements. The exact cause of chronic idiopathic constipation is unknown. The symptoms of this condition may be exacerbated by lifestyle factors, such as a low-fiber diet, dehydration, lack of physical activity, and certain medications. The Rome IV criteria, which is widely used in diagnosing functional gastrointestinal disorders, is also used for identifying chronic idiopathic constipation.

Chronic Idiopathic Constipation (CIC): Treatment Overview

Chronic idiopathic constipation is typically treated with a combination of medications, lifestyle changes, and in some cases, medical procedures. Over-the-counter laxatives including osmotic laxatives (polyethylene glycol, lactulose), stimulant laxatives (bisacodyl, senna), and lubricant laxatives (mineral oil) are commonly used to treat the condition. Prescription medications such as prokinetic agents, 5-HT4 receptor agonists, and chloride channel activators are given to patients who do not respond to over-the-counter treatments.

Epidemiology

The chronic idiopathic constipation (CIC) epidemiology section offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. Expert Market Research provides both current and predicted trends for chronic idiopathic constipation (CIC) by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for chronic idiopathic constipation (CIC) and their trends. The data is broken down into specific categories, such as the total diagnosed cases across different age groups and patient pools.

• A 2023 United States survey found Rome IV chronic idiopathic constipation is more common (6.0%) than Rome IV opioid-induced constipation (1.7%) and opioid-exacerbated constipation (0.4%).
• According to a population-based survey on chronic constipation in the United States (2020), 3 out of 5 Americans with constipation have never discussed their symptoms with a healthcare provider, showing that most of the affected patients rely on over-the-counter treatments, with low use of prescription medications.
• As per Black, C. J., & Ford, A. C. (2018), chronic idiopathic constipation affects 14% of the population globally. It has three subtypes: normal transit constipation, slow transit constipation, and dyssynergic defecation, out of which normal transit constipation is the most common subtype.
• Various studies show that chronic idiopathic constipation affects 10% to 17% of the global population. The condition is more common in women and older adults and often leads to debilitating symptoms.

Country-wise Chronic Idiopathic Constipation (CIC) Epidemiology

The chronic idiopathic constipation (CIC) epidemiology data and findings for the United States, EU-4 (Germany, Spain, Italy, France), the United Kingdom, Japan, and India are also provided in the epidemiology section.

The epidemiology of chronic idiopathic constipation (CIC) varies significantly between countries due to differences in diet, lifestyle, genetic predisposition, healthcare access, and diagnostic criteria. In the United States, around 35 million adults may experience chronic idiopathic constipation. It is reported to be more common in women (56%) and adults over 35 years (84%). Studies also reveal that Caucasians are more affected (82%) than other races and ethnicities.

Country Specific Stats:

Scope of the Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of chronic idiopathic constipation (CIC) based on several factors.
• Chronic Idiopathic Constipation (CIC) Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The report helps to identify the patient population, and the unmet needs of chronic idiopathic constipation (CIC) are highlighted along with an assessment of the disease's risk and burden.

Key Questions Answered

• What are the key findings of chronic idiopathic constipation (CIC) epidemiology in the 8 major markets?
• What will be the total number of patients with chronic idiopathic constipation (CIC) across the 8 major markets during the forecast period?
• What was the country-wise prevalence of chronic idiopathic constipation (CIC) in the 8 major markets in the historical period?
• Which country will have the highest number of chronic idiopathic constipation (CIC) patients during the forecast period of 2025-2034?
• Which key factors would influence the shift in the patient population of chronic idiopathic constipation (CIC) during the forecast period of 2025-2034?
• What are the currently available treatments for chronic idiopathic constipation (CIC)?
• What are the disease risks, signs, symptoms, and unmet needs of chronic idiopathic constipation (CIC)?

Related Reports

Global Opioid Induced Constipation Market

Constipation Treatment Market